{"transactions":[{"id":705161,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-22T00:37:32.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":10826,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026."}],"balance_after":10826,"derivative":{"exercise_price":12.64,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":10826},"source":{"system":"sec-edgar","filing":"0001193125-26-310978","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000119312526310978/ownership.xml","form_type":"4/A","original_submission_date":"2026-06-16"}},{"id":736031,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-16T20:30:38.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":9810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":9810,"derivative":{"exercise_price":12.64,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":9810},"source":{"system":"sec-edgar","filing":"0001193125-26-272700","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000119312526272700/ownership.xml","form_type":"4"}},{"id":944556,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T21:23:21.000Z","date":"2026-01-05","kind":"grant","planned":false,"acquired":true,"shares":4982706,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date."}],"balance_after":4982706,"derivative":{"exercise_price":2.01,"expiration_date":"2036-01-05","underlying":"Common Stock","underlying_shares":4982706},"source":{"system":"sec-edgar","filing":"0001193125-26-006351","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526006351/ownership.xml","form_type":"4"}},{"id":971095,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-12T23:52:48.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":13.35,"expiration_date":"2029-06-12","underlying":"Common Shares","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001193125-25-317936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000119312525317936/ownership.xml","form_type":"4"}},{"id":971094,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-12T23:52:48.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4983,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":23.3,"expiration_date":"2028-07-20","underlying":"Common Shares","underlying_shares":4983},"source":{"system":"sec-edgar","filing":"0001193125-25-317936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000119312525317936/ownership.xml","form_type":"4"}},{"id":971093,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-12T23:52:48.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":19.12,"expiration_date":"2027-05-24","underlying":"Common Shares","underlying_shares":5650},"source":{"system":"sec-edgar","filing":"0001193125-25-317936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000119312525317936/ownership.xml","form_type":"4"}},{"id":971092,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-12T23:52:48.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8631,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":16.09,"expiration_date":"2030-06-30","underlying":"Common Shares","underlying_shares":8631},"source":{"system":"sec-edgar","filing":"0001193125-25-317936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000119312525317936/ownership.xml","form_type":"4"}},{"id":971091,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-12T23:52:48.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":21.15,"expiration_date":"2031-05-28","underlying":"Common Shares","underlying_shares":6120},"source":{"system":"sec-edgar","filing":"0001193125-25-317936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000119312525317936/ownership.xml","form_type":"4"}},{"id":971090,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-12T23:52:48.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":18.56,"expiration_date":"2032-05-31","underlying":"Common Shares","underlying_shares":16604},"source":{"system":"sec-edgar","filing":"0001193125-25-317936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000119312525317936/ownership.xml","form_type":"4"}},{"id":971089,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-12T23:52:48.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":23.29,"expiration_date":"2033-06-08","underlying":"Common Shares","underlying_shares":14414},"source":{"system":"sec-edgar","filing":"0001193125-25-317936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000119312525317936/ownership.xml","form_type":"4"}},{"id":971088,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-12T23:52:48.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":48.73,"expiration_date":"2034-05-07","underlying":"Common Shares","underlying_shares":8844},"source":{"system":"sec-edgar","filing":"0001193125-25-317936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000119312525317936/ownership.xml","form_type":"4"}},{"id":971087,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-12T23:52:48.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13193,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":41.6,"expiration_date":"2035-05-22","underlying":"Common Shares","underlying_shares":13193},"source":{"system":"sec-edgar","filing":"0001193125-25-317936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000119312525317936/ownership.xml","form_type":"4"}},{"id":971086,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-12-12T23:52:48.000Z","date":"2025-12-12","kind":"other","planned":false,"acquired":false,"shares":73576,"price":97,"value":7136872.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 29, 2025, Merus N.V. (the \"Issuer\") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the \"Transaction Agreement\") with Genmab A/S (\"Genmab\") and its wholly owned subsidiary, Genmab Holding II B.V. (the \"Purchaser\"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the \"Shares\"), of the Issuer (the \"Offer\"), and, on December 12, 2025 (the \"Acceptance Time\"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the \"Offer Consideration\"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-317936","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000119312525317936/ownership.xml","form_type":"4"}},{"id":976179,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:14:39.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":76227,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":0.615,"expiration_date":"2028-10-18","underlying":"Common Stock","underlying_shares":76227},"source":{"system":"sec-edgar","filing":"0001193125-25-312115","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312115/ownership.xml","form_type":"4"}},{"id":976178,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:14:39.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11493,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":6.364,"expiration_date":"2029-01-16","underlying":"Common Stock","underlying_shares":11493},"source":{"system":"sec-edgar","filing":"0001193125-25-312115","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312115/ownership.xml","form_type":"4"}},{"id":976177,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:14:39.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":70587,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.009,"expiration_date":"2029-04-26","underlying":"Common Stock","underlying_shares":70587},"source":{"system":"sec-edgar","filing":"0001193125-25-312115","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312115/ownership.xml","form_type":"4"}},{"id":976176,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:14:39.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":25.2,"expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001193125-25-312115","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312115/ownership.xml","form_type":"4"}},{"id":976175,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:14:39.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":26.32,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001193125-25-312115","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312115/ownership.xml","form_type":"4"}},{"id":976174,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:14:39.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":8.13,"expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-25-312115","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312115/ownership.xml","form_type":"4"}},{"id":976173,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:14:39.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":50.83,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-25-312115","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312115/ownership.xml","form_type":"4"}},{"id":976172,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:14:39.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":23.02,"expiration_date":"2034-06-08","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001193125-25-312115","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312115/ownership.xml","form_type":"4"}},{"id":976171,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T10:14:39.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9398,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NN Invest Sub, Inc, a Delaware corporation and a direct or indirect wholly owned subsidiary of Novo (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025 (such date and time of such Merger, the \"Effective Time\"), with the Issuer surviving the Merger as a direct or indirect wholly owned subsidiary of Novo."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units (\"Company RSUs\") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer (\"Company Common Stock\") upon vesting of the Company RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00 (the \"Closing Consideration\") and (ii) one contractual contingent value right (a \"CVR\") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement), without interest and subject to any withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-312115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312115/ownership.xml","form_type":"4"}},{"id":1013201,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-28T01:26:20.000Z","date":"2025-10-23","kind":"grant","planned":false,"acquired":true,"shares":53521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":53521,"derivative":{"exercise_price":2.8,"expiration_date":"2035-10-22","underlying":"Common Stock","underlying_shares":53521},"source":{"system":"sec-edgar","filing":"0001193125-25-251994","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000119312525251994/ownership.xml","form_type":"4"}},{"id":1013799,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-25T00:00:13.000Z","date":"2025-10-23","kind":"sale","planned":false,"acquired":false,"shares":154894,"price":0.81,"value":125464.14,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.78 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 103,540 unvested RSUs."}],"balance_after":103540,"source":{"system":"sec-edgar","filing":"0001415537-25-000004","document":"form4-10242025_081010.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141553725000004/form4-10242025_081010.xml","form_type":"4"}},{"id":1066665,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-08-14T16:06:58.000Z","date":"2025-08-11","kind":"other","planned":false,"acquired":false,"shares":83296,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":83296},"source":{"system":"sec-edgar","filing":"0001415889-25-021822","document":"form4-08142025_080855.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000141588925021822/form4-08142025_080855.xml","form_type":"4"}},{"id":1066664,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-14T16:06:58.000Z","date":"2025-08-11","kind":"other","planned":false,"acquired":false,"shares":128631,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reporting person received a liquidation distribution of $5.35 per share of Common Stock from Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-021822","document":"form4-08142025_080855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000141588925021822/form4-08142025_080855.xml","form_type":"4"}},{"id":1095289,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T23:56:12.000Z","date":"2025-02-21","kind":"grant","planned":false,"acquired":true,"shares":602346,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported the incorrect exercise price and expiration date with respect to the stock option award originally granted on February 21, 2025 (the \"Option Award\"). This amendment is being filed solely to correct the exercise price and expiration date of the Option Award."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest and become exercisable in 48 substantially equal monthly installments beginning on March 21, 2025, subject to the Reporting Person's continued employment through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported the incorrect exercise price and expiration date with respect to the stock option award originally granted on February 21, 2025 (the \"Option Award\"). This amendment is being filed solely to correct the exercise price and expiration date of the Option Award."}],"balance_after":602346,"derivative":{"exercise_price":2.97,"expiration_date":"2035-02-21","underlying":"Common Stock","underlying_shares":602346},"source":{"system":"sec-edgar","filing":"0000950170-25-093441","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025093441/ownership.xml","form_type":"4/A","original_submission_date":"2025-02-25"}},{"id":1101034,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-27T00:00:11.000Z","date":"2025-06-24","kind":"sale","planned":false,"acquired":false,"shares":13227,"price":4.01,"value":53040.27,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 103,540 unvested RSUs."}],"balance_after":258433,"source":{"system":"sec-edgar","filing":"0001415889-25-018317","document":"form4-06262025_080601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925018317/form4-06262025_080601.xml","form_type":"4"}},{"id":1107898,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T00:00:15.000Z","date":"2025-06-15","kind":"grant","planned":false,"acquired":true,"shares":5450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026."}],"balance_after":5450,"derivative":{"exercise_price":4.3,"expiration_date":"2035-06-14","underlying":"Common Stock","underlying_shares":5450},"source":{"system":"sec-edgar","filing":"0001415889-25-017615","document":"form4-06172025_080611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925017615/form4-06172025_080611.xml","form_type":"4"}},{"id":1107897,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T00:00:15.000Z","date":"2025-06-15","kind":"grant","planned":false,"acquired":true,"shares":2450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 156,492 unvested RSUs."}],"balance_after":271660,"source":{"system":"sec-edgar","filing":"0001415889-25-017615","document":"form4-06172025_080611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925017615/form4-06172025_080611.xml","form_type":"4"}},{"id":1121250,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T01:44:38.000Z","date":"2025-06-03","kind":"sale","planned":false,"acquired":false,"shares":10866,"price":3.74,"value":40638.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"This amendment is being filed solely to correct the nature of the transaction reported in Column 4 of Table I of the Form 4 filed by the Reporting Person on June 4, 2025. As reported in this amendment, such transaction resulted in a \"disposition\" of common stock by the Reporting Person and not an \"acquisition\" as previously reported."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 154,042 unvested RSUs."}],"balance_after":269210,"source":{"system":"sec-edgar","filing":"0001104659-25-056986","document":"tm2517328-2_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000110465925056986/tm2517328-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-06-04"}},{"id":1121426,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T16:06:04.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":9398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest in full on the earlier of (i) June 3, 2026, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board."}],"balance_after":9398,"source":{"system":"sec-edgar","filing":"0000950170-25-082309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025082309/ownership.xml","form_type":"4"}},{"id":1122812,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T00:00:09.000Z","date":"2025-06-03","kind":"sale","planned":false,"acquired":true,"shares":10866,"price":3.74,"value":40638.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 154,042 unvested RSUs."}],"balance_after":269210,"source":{"system":"sec-edgar","filing":"0001415889-25-015677","document":"form4-06042025_080601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925015677/form4-06042025_080601.xml","form_type":"4"}},{"id":1133279,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-05-27T12:00:04.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":13193,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest over a one-year period commencing on May 22, 2025 in 12 equal monthly installments."}],"balance_after":13193,"derivative":{"exercise_price":41.6,"expiration_date":"2035-05-22","underlying":"Common Shares","underlying_shares":13193},"source":{"system":"sec-edgar","filing":"0000950170-25-077380","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000095017025077380/ownership.xml","form_type":"4"}},{"id":1242768,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T02:57:57.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":25534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":25534,"derivative":{"exercise_price":2.54,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":25534},"source":{"system":"sec-edgar","filing":"0000950170-25-028253","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000095017025028253/ownership.xml","form_type":"4"}},{"id":1242767,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T02:57:57.000Z","date":"2025-02-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":16.82,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":25534},"source":{"system":"sec-edgar","filing":"0000950170-25-028253","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000095017025028253/ownership.xml","form_type":"4"}},{"id":1242766,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T02:57:57.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":7615,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":7615,"derivative":{"exercise_price":2.54,"expiration_date":"2031-12-16","underlying":"Common Stock","underlying_shares":7615},"source":{"system":"sec-edgar","filing":"0000950170-25-028253","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000095017025028253/ownership.xml","form_type":"4"}},{"id":1242765,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T02:57:57.000Z","date":"2025-02-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7615,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.29,"expiration_date":"2031-12-16","underlying":"Common Stock","underlying_shares":7615},"source":{"system":"sec-edgar","filing":"0000950170-25-028253","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000095017025028253/ownership.xml","form_type":"4"}},{"id":1242764,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T02:57:57.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":37222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":37222,"derivative":{"exercise_price":2.54,"expiration_date":"2031-01-21","underlying":"Common Stock","underlying_shares":37222},"source":{"system":"sec-edgar","filing":"0000950170-25-028253","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000095017025028253/ownership.xml","form_type":"4"}},{"id":1242763,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T02:57:57.000Z","date":"2025-02-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 24, 2025, the Issuer's board of directors approved an option repricing (\"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the \"2017 Plan\") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the \"2024 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.29,"expiration_date":"2031-01-21","underlying":"Common Stock","underlying_shares":37222},"source":{"system":"sec-edgar","filing":"0000950170-25-028253","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000095017025028253/ownership.xml","form_type":"4"}},{"id":1246365,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-25T21:05:24.000Z","date":"2025-02-21","kind":"grant","planned":false,"acquired":true,"shares":602346,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest and become exercisable in 48 substantially equal monthly installments beginning on March 21, 2025, subject to the Reporting Person's continued employment through such date."}],"balance_after":602346,"derivative":{"exercise_price":2.23,"expiration_date":"2035-02-14","underlying":"Common Stock","underlying_shares":602346},"source":{"system":"sec-edgar","filing":"0000950170-25-026627","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025026627/ownership.xml","form_type":"4"}},{"id":1260156,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T01:26:03.000Z","date":"2025-02-17","kind":"grant","planned":false,"acquired":true,"shares":1794291,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest and become exercisable in 48 substantially equal monthly installments beginning on March 12, 2025, subject to the Reporting Person's continued employment through such date."}],"balance_after":1794291,"derivative":{"exercise_price":2.35,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":1794291},"source":{"system":"sec-edgar","filing":"0000950170-25-023600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025023600/ownership.xml","form_type":"4"}},{"id":1260155,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T01:26:03.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":4373857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest and become exercisable in 48 substantially equal monthly installments beginning on March 12, 2025, subject to the Reporting Person's continued employment through such date."}],"balance_after":4373857,"derivative":{"exercise_price":2.35,"expiration_date":"2035-02-14","underlying":"Common Stock","underlying_shares":4373857},"source":{"system":"sec-edgar","filing":"0000950170-25-023600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025023600/ownership.xml","form_type":"4"}},{"id":1307938,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-08T01:12:59.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":99500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 6, 2025 and vests over four years beginning on the vesting commencement date of January 6, 2025, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 6, 2029, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":99500,"derivative":{"exercise_price":7.53,"expiration_date":"2035-01-05","underlying":"Common Stock","underlying_shares":99500},"source":{"system":"sec-edgar","filing":"0001415889-25-001060","document":"form4-01082025_010156.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001060/form4-01082025_010156.xml","form_type":"4"}},{"id":1307937,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-01-08T01:12:59.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":5779,"price":7.63,"value":44093.77,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 194,739 unvested RSUs."}],"balance_after":280076,"source":{"system":"sec-edgar","filing":"0001415889-25-001060","document":"form4-01082025_010156.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001060/form4-01082025_010156.xml","form_type":"4"}},{"id":1307936,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-01-08T01:12:59.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":22100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 6, 2026, as to 1/3 of the shares underlying the RSUs on January 6, 2027 and as to the final 1/3 of shares underlying the RSUs on January 6, 2028."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 194,739 unvested RSUs."}],"balance_after":285855,"source":{"system":"sec-edgar","filing":"0001415889-25-001060","document":"form4-01082025_010156.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001060/form4-01082025_010156.xml","form_type":"4"}},{"id":1468095,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-06-28T00:00:07.000Z","date":"2024-06-26","kind":"sale","planned":false,"acquired":false,"shares":15168,"price":4.75,"value":72048.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $5.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 191,304 unvested RSUs."}],"balance_after":263755,"source":{"system":"sec-edgar","filing":"0001415889-24-018374","document":"form4-06272024_080604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924018374/form4-06272024_080604.xml","form_type":"4"}},{"id":1483551,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T17:28:06.000Z","date":"2024-06-08","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on the earlier of (i) June 7, 2025, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board."}],"balance_after":26000,"derivative":{"exercise_price":23.02,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0000950170-24-072075","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024072075/ownership.xml","form_type":"4"}},{"id":1485222,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-06-10T16:24:33.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (a) June 6, 2025 and (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":20000,"derivative":{"exercise_price":13.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-24-016217","document":"form4-06102024_080630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000141588924016217/form4-06102024_080630.xml","form_type":"4"}},{"id":1486975,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T22:00:12.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 5, 2025 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":18.9,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-24-016055","document":"form4-06072024_060608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000141588924016055/form4-06072024_060608.xml","form_type":"4"}},{"id":1495044,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-06-04T00:00:06.000Z","date":"2024-05-31","kind":"sale","planned":false,"acquired":false,"shares":7392,"price":6.09,"value":45017.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 244,256 unvested RSUs."}],"balance_after":278923,"source":{"system":"sec-edgar","filing":"0001415889-24-015222","document":"form4-06032024_080602.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924015222/form4-06032024_080602.xml","form_type":"4"}},{"id":1522034,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2024-05-09T20:30:24.000Z","date":"2024-05-07","kind":"grant","planned":false,"acquired":true,"shares":8844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest over a one-year period commencing May 7, 2024 in 12 equal monthly installments."}],"balance_after":8844,"derivative":{"exercise_price":48.73,"expiration_date":"2034-05-07","underlying":"Common Shares","underlying_shares":8844},"source":{"system":"sec-edgar","filing":"0000950170-24-057082","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000095017024057082/ownership.xml","form_type":"4"}},{"id":1559423,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T21:40:32.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":25534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":25534,"derivative":{"exercise_price":16.82,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":25534},"source":{"system":"sec-edgar","filing":"0000950170-24-037399","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000095017024037399/ownership.xml","form_type":"4"}},{"id":1685440,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T21:04:45.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":64500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on January 4, 2024 and vests over four years beginning on the vesting commencement date of January 4, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 4, 2028, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":64500,"derivative":{"exercise_price":7,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":64500},"source":{"system":"sec-edgar","filing":"0001415889-24-000769","document":"form4-01052024_090140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000769/form4-01052024_090140.xml","form_type":"4"}},{"id":1685439,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-01-05T21:04:45.000Z","date":"2024-01-04","kind":"sale","planned":false,"acquired":false,"shares":4539,"price":6.73,"value":30547.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $6.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 272,690 unvested RSUs."}],"balance_after":286315,"source":{"system":"sec-edgar","filing":"0001415889-24-000769","document":"form4-01052024_090140.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000769/form4-01052024_090140.xml","form_type":"4"}},{"id":1685438,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-01-05T21:04:45.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":14300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2025, as to 1/3 of the shares underlying the RSUs on January 4, 2026 and as to the final 1/3 of shares underlying the RSUs on January 4, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 287,095 unvested RSUs."}],"balance_after":290854,"source":{"system":"sec-edgar","filing":"0001415889-24-000769","document":"form4-01052024_090140.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000769/form4-01052024_090140.xml","form_type":"4"}},{"id":1843492,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-27T17:39:52.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 23, 2024 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":15000,"derivative":{"exercise_price":50.83,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-23-030209","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023030209/ownership.xml","form_type":"4"}},{"id":1845133,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-24T00:00:07.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":211831,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter."}],"balance_after":211831,"derivative":{"exercise_price":14.56,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":211831},"source":{"system":"sec-edgar","filing":"0001415889-23-010281","document":"form4-06232023_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923010281/form4-06232023_080601.xml","form_type":"4"}},{"id":1845132,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-06-24T00:00:07.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":158873,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 272,795 unvested RSUs."}],"balance_after":276554,"source":{"system":"sec-edgar","filing":"0001415889-23-010281","document":"form4-06232023_080601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923010281/form4-06232023_080601.xml","form_type":"4"}},{"id":1858606,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2023-06-12T20:16:05.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":14414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest over a one-year period commencing June 8, 2023 in 12 equal monthly installments."}],"balance_after":14414,"derivative":{"exercise_price":23.29,"expiration_date":"2033-06-08","underlying":"Common Shares","underlying_shares":14414},"source":{"system":"sec-edgar","filing":"0001209191-23-036268","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000120919123036268/doc4.xml","form_type":"4"}},{"id":1862516,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-08T22:00:14.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 6, 2024 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":16.3,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-23-009443","document":"form4-06082023_060603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000141588923009443/form4-06082023_060603.xml","form_type":"4"}},{"id":1862752,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T16:18:05.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (a) June 6, 2024 and (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":16250,"derivative":{"exercise_price":5.03,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0001209191-23-035382","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000120919123035382/doc4.xml","form_type":"4"}},{"id":1869648,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-03T00:00:12.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2268,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The canceled option was granted on January 3, 2022 and provided for the purchase of up to 5,670 shares of common stock of the issuer based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters, of which, prior to the option exchange program, options to purchase 1,512 shares had vested, options to purchase 3,024 shares had been forfeited and options to purchase up to 1,134 shares were unvested assuming maximum level of achievement (options to purchase 756 shares were unvested assuming target level of achievement). The vested portion of the option and the unvested portion of the option assuming target level of achievement were eligible for the issuer's option exchange program."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":68.5,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":2268},"source":{"system":"sec-edgar","filing":"0001415889-23-009133","document":"form4-06022023_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009133/form4-06022023_080601.xml","form_type":"4"}},{"id":1869647,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-03T00:00:12.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15499,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The canceled option was granted on January 3, 2022 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":68.5,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":15499},"source":{"system":"sec-edgar","filing":"0001415889-23-009133","document":"form4-06022023_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009133/form4-06022023_080601.xml","form_type":"4"}},{"id":1869646,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-03T00:00:12.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6059,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The canceled option was granted on January 4, 2021 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":343,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":6059},"source":{"system":"sec-edgar","filing":"0001415889-23-009133","document":"form4-06022023_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009133/form4-06022023_080601.xml","form_type":"4"}},{"id":1869645,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-03T00:00:12.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7299,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The canceled option was granted on January 2, 2020 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":192,"expiration_date":"2030-01-01","underlying":"Common Stock","underlying_shares":7299},"source":{"system":"sec-edgar","filing":"0001415889-23-009133","document":"form4-06022023_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009133/form4-06022023_080601.xml","form_type":"4"}},{"id":1869644,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-03T00:00:12.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9199,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The canceled option was granted on January 2, 2019 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":259.5,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":9199},"source":{"system":"sec-edgar","filing":"0001415889-23-009133","document":"form4-06022023_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009133/form4-06022023_080601.xml","form_type":"4"}},{"id":1869643,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-03T00:00:12.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4599,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The canceled option was granted on February 7, 2018 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":643,"expiration_date":"2028-02-06","underlying":"Common Stock","underlying_shares":4599},"source":{"system":"sec-edgar","filing":"0001415889-23-009133","document":"form4-06022023_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009133/form4-06022023_080601.xml","form_type":"4"}},{"id":1869642,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-03T00:00:12.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1572,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The canceled option was granted on July 19, 2017 and provided for vesting over four years with 1/48th of the shares underlying the option vested on August 31, 2017 and an additional 1/48th of the shares vested at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":750,"expiration_date":"2027-07-18","underlying":"Common Stock","underlying_shares":1572},"source":{"system":"sec-edgar","filing":"0001415889-23-009133","document":"form4-06022023_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009133/form4-06022023_080601.xml","form_type":"4"}},{"id":1869641,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-03T00:00:12.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12195,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The canceled option was granted on June 17, 2016 and provided for vesting over four years with 1/48th of the shares underlying the option vested on April 8, 2015 and an additional 1/48th of the shares vested at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":167,"expiration_date":"2026-06-17","underlying":"Common Stock","underlying_shares":12195},"source":{"system":"sec-edgar","filing":"0001415889-23-009133","document":"form4-06022023_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009133/form4-06022023_080601.xml","form_type":"4"}},{"id":1869640,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-03T00:00:12.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7576,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The canceled option was granted on September 15, 2015 and provided for vesting over four years with 25% of the shares underlying the option vested on April 8, 2016 and 1/48th of the shares vested at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":260.5,"expiration_date":"2025-09-11","underlying":"Common Stock","underlying_shares":7576},"source":{"system":"sec-edgar","filing":"0001415889-23-009133","document":"form4-06022023_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009133/form4-06022023_080601.xml","form_type":"4"}},{"id":1869639,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-03T00:00:12.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5449,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The canceled option was granted on June 4, 2015 and provided for vesting over four years with 1/48th of the shares underlying the option vested on May 8, 2015 and an additional 1/48th of the shares vested at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":167,"expiration_date":"2025-06-03","underlying":"Common Stock","underlying_shares":5449},"source":{"system":"sec-edgar","filing":"0001415889-23-009133","document":"form4-06022023_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009133/form4-06022023_080601.xml","form_type":"4"}},{"id":1869638,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-06-03T00:00:12.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":71715,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 113,922 unvested RSUs."}],"balance_after":117681,"source":{"system":"sec-edgar","filing":"0001415889-23-009133","document":"form4-06022023_080601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009133/form4-06022023_080601.xml","form_type":"4"}},{"id":1918915,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2023-04-17T12:26:42.000Z","date":"2023-04-14","kind":"exercise","planned":false,"acquired":false,"shares":36632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options vest over a four-year period commencing August 21, 2015. 25% vest after one year and in 36 equal installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":7.97,"expiration_date":"2023-08-19","underlying":"Common Shares","underlying_shares":36632},"source":{"system":"sec-edgar","filing":"0001209191-23-024393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000120919123024393/doc4.xml","form_type":"4"}},{"id":1918914,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2023-04-17T12:26:42.000Z","date":"2023-04-14","kind":"exercise","planned":false,"acquired":false,"shares":36944,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest over a four-year period commencing June 6, 2015. 25% vest after one year and in 36 equal installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":6.57,"expiration_date":"2023-06-02","underlying":"Common Shares","underlying_shares":36944},"source":{"system":"sec-edgar","filing":"0001209191-23-024393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000120919123024393/doc4.xml","form_type":"4"}},{"id":1918913,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-04-17T12:26:42.000Z","date":"2023-04-14","kind":"exercise","planned":false,"acquired":true,"shares":36632,"price":7.97,"value":291957.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Exercise price is denominated in Euros. Exchange rate of 1.1057 used to convert to USD."}],"balance_after":73576,"source":{"system":"sec-edgar","filing":"0001209191-23-024393","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000120919123024393/doc4.xml","form_type":"4"}},{"id":1918912,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-04-17T12:26:42.000Z","date":"2023-04-14","kind":"exercise","planned":false,"acquired":true,"shares":36944,"price":6.57,"value":242722.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Exercise price is denominated in Euros. Exchange rate of 1.1057 used to convert to USD."}],"balance_after":36944,"source":{"system":"sec-edgar","filing":"0001209191-23-024393","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000120919123024393/doc4.xml","form_type":"4"}},{"id":1952144,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-16T00:00:10.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":1512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 3, 2022, the Reporting Person was granted an option to purchase up to 5,670 shares of common stock of the Issuer. Specified portions of the options vest based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2023, the Compensation Committee of the Issuer's Board of Directors determined that certain of the performance conditions were achieved at specific levels of achievement, resulting in vesting of the option as to 1,512 shares of common stock. The Compensation Committee has made no determination with respect to certain performance metrics, which could result in the further vesting of up to 1,134 shares of common stock underlying the option."}],"balance_after":1512,"derivative":{"exercise_price":68.5,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":1512},"source":{"system":"sec-edgar","filing":"0001415889-23-004973","document":"form4-03152023_080301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923004973/form4-03152023_080301.xml","form_type":"4"}},{"id":1963660,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-08T17:02:25.000Z","date":"2023-03-06","kind":"grant","acquired":true,"shares":13667,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":13667,"derivative":{"exercise_price":4.2,"expiration_date":"2032-10-25","underlying":"Common Stock","underlying_shares":13667},"source":{"system":"sec-edgar","filing":"0001209191-23-017237","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000120919123017237/doc4.xml","form_type":"4"}},{"id":1963659,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-08T17:02:25.000Z","date":"2023-03-06","kind":"disposition_to_issuer","acquired":false,"shares":13667,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":0,"derivative":{"exercise_price":17.83,"expiration_date":"2032-10-25","underlying":"Common Stock","underlying_shares":13667},"source":{"system":"sec-edgar","filing":"0001209191-23-017237","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000120919123017237/doc4.xml","form_type":"4"}},{"id":1963658,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-08T17:02:25.000Z","date":"2023-03-06","kind":"grant","acquired":true,"shares":35413,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"6.25% vest in quarterly installments over the 4-year period commencing on February 17, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":35413,"derivative":{"exercise_price":4.2,"expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":35413},"source":{"system":"sec-edgar","filing":"0001209191-23-017237","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000120919123017237/doc4.xml","form_type":"4"}},{"id":1963657,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-08T17:02:25.000Z","date":"2023-03-06","kind":"disposition_to_issuer","acquired":false,"shares":35413,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"6.25% vest in quarterly installments over the 4-year period commencing on February 17, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.22,"expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":35413},"source":{"system":"sec-edgar","filing":"0001209191-23-017237","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000120919123017237/doc4.xml","form_type":"4"}},{"id":2060325,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-01-07T01:00:16.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":198,"price":28.54,"value":5650.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units (\"RSUs\") granted on January 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.52 to $28.71, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 42,207 unvested RSUs."}],"balance_after":45966,"source":{"system":"sec-edgar","filing":"0001415889-23-000636","document":"form4-01062023_080102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923000636/form4-01062023_080102.xml","form_type":"4"}},{"id":2060324,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-01-07T01:00:16.000Z","date":"2023-01-04","kind":"grant","acquired":true,"shares":41700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 42,714 unvested RSUs."}],"balance_after":46164,"source":{"system":"sec-edgar","filing":"0001415889-23-000636","document":"form4-01062023_080102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923000636/form4-01062023_080102.xml","form_type":"4"}},{"id":2130314,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-10-28T20:15:18.000Z","date":"2022-10-26","kind":"sale","acquired":false,"shares":561,"price":6.52,"value":3657.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units (\"RSUs\") granted on June 25, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.62, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,014 unvested RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":4464,"source":{"system":"sec-edgar","filing":"0001415889-22-010878","document":"form4-10282022_041001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588922010878/form4-10282022_041001.xml","form_type":"4"}},{"id":2131149,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-10-27T16:55:24.000Z","date":"2022-10-26","kind":"grant","acquired":true,"shares":13667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":13667,"derivative":{"exercise_price":17.83,"expiration_date":"2032-10-25","underlying":"Common Stock","underlying_shares":13667},"source":{"system":"sec-edgar","filing":"0001209191-22-054728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000120919122054728/doc4.xml","form_type":"4"}},{"id":2219340,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-06-30T00:09:32.000Z","date":"2022-06-27","kind":"sale","acquired":false,"shares":7975,"price":0.37,"value":2950.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 139,819 unvested RSUs."}],"balance_after":251183,"source":{"system":"sec-edgar","filing":"0001415889-22-007059","document":"form4-06292022_050622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588922007059/form4-06292022_050622.xml","form_type":"4"}},{"id":2224229,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T21:00:59.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 21, 2023 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":12.26,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-22-017510","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000149315222017510/ownership.xml","form_type":"4"}},{"id":2244914,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T16:06:19.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 2, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":15000,"derivative":{"exercise_price":8.13,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-22-020941","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322020941/doc4.xml","form_type":"4"}},{"id":2247308,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2022-06-02T20:05:20.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":16604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest over a one-year period commencing May 31, 2022 in 12 equal monthly installments."}],"balance_after":16604,"derivative":{"exercise_price":18.56,"expiration_date":"2032-05-31","underlying":"Common Shares","underlying_shares":16604},"source":{"system":"sec-edgar","filing":"0000899243-22-020664","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000089924322020664/doc4.xml","form_type":"4"}},{"id":2443833,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T01:00:21.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":775000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on January 3, 2022 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."}],"balance_after":775000,"derivative":{"exercise_price":1.37,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":775000},"source":{"system":"sec-edgar","filing":"0001415889-22-000402","document":"form4-01052022_080111.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588922000402/form4-01052022_080111.xml","form_type":"4"}},{"id":2443832,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-01-06T01:00:21.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":9518,"price":1.3,"value":12373.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units granted on January 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.25 to $1.39, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 164,599 unvested RSUs."}],"balance_after":259158,"source":{"system":"sec-edgar","filing":"0001415889-22-000402","document":"form4-01052022_080111.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588922000402/form4-01052022_080111.xml","form_type":"4"}},{"id":2532757,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2021-10-29T00:01:53.000Z","date":"2021-10-26","kind":"sale","acquired":false,"shares":27598,"price":1.8,"value":49676.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units (\"RSUs\") granted on June 25, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.89, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 189,930 unvested RSUs."}],"balance_after":268676,"source":{"system":"sec-edgar","filing":"0001415889-21-005009","document":"form4-10282021_051046.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588921005009/form4-10282021_051046.xml","form_type":"4"}},{"id":2647903,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-01T22:33:28.000Z","date":"2021-06-29","kind":"grant","acquired":true,"shares":42200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on July 29, 2021."}],"balance_after":42200,"derivative":{"exercise_price":14,"expiration_date":"2031-06-28","underlying":"Common Stock","underlying_shares":42200},"source":{"system":"sec-edgar","filing":"0001104659-21-088381","document":"tm2121189-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000110465921088381/tm2121189-6_4seq1.xml","form_type":"4"}},{"id":2647902,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-01T22:33:28.000Z","date":"2021-04-02","kind":"grant","acquired":true,"shares":76747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the \"Reverse Split\"). This amount has been adjusted to give effect to the Reverse Split."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F1","text":"On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the \"Reverse Split\"). This amount has been adjusted to give effect to the Reverse Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on July 4, 2021."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the \"Reverse Split\"). This amount has been adjusted to give effect to the Reverse Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the \"Reverse Split\"). This amount has been adjusted to give effect to the Reverse Split."}],"balance_after":76747,"derivative":{"exercise_price":2.144,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":76747},"source":{"system":"sec-edgar","filing":"0001104659-21-088381","document":"tm2121189-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000110465921088381/tm2121189-6_4seq1.xml","form_type":"4"}},{"id":2647901,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-01T22:33:28.000Z","date":"2021-04-02","kind":"grant","acquired":true,"shares":39550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the \"Reverse Split\"). This amount has been adjusted to give effect to the Reverse Split."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F1","text":"On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the \"Reverse Split\"). This amount has been adjusted to give effect to the Reverse Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vested on March 12, 2021."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the \"Reverse Split\"). This amount has been adjusted to give effect to the Reverse Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the \"Reverse Split\"). This amount has been adjusted to give effect to the Reverse Split."}],"balance_after":39550,"derivative":{"exercise_price":2.144,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":39550},"source":{"system":"sec-edgar","filing":"0001104659-21-088381","document":"tm2121189-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000110465921088381/tm2121189-6_4seq1.xml","form_type":"4"}},{"id":2651671,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2021-06-29T21:25:28.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":7586,"price":5.77,"value":43771.22,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 279,080 unvested RSUs."}],"balance_after":296274,"source":{"system":"sec-edgar","filing":"0001415889-21-003256","document":"form4-06292021_050601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588921003256/form4-06292021_050601.xml","form_type":"4"}},{"id":2683497,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-03T17:58:49.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":13000,"derivative":{"exercise_price":26.32,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001104659-21-076501","document":"tm2118278-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465921076501/tm2118278-7_4seq1.xml","form_type":"4"}},{"id":2686218,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2021-06-02T20:10:29.000Z","date":"2021-05-28","kind":"grant","acquired":true,"shares":6120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest over a one-year period commencing May 28, 2021 in 12 equal monthly installments."}],"balance_after":6120,"derivative":{"exercise_price":21.15,"expiration_date":"2031-05-28","underlying":"Common Shares","underlying_shares":6120},"source":{"system":"sec-edgar","filing":"0000899243-21-021547","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000089924321021547/doc4.xml","form_type":"4"}},{"id":2888462,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-02T02:45:53.000Z","date":"2021-01-28","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan."}],"balance_after":15000,"derivative":{"exercise_price":1.47,"expiration_date":"2031-01-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-21-002329","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415537/000149315221002329/ownership.xml","form_type":"4"}}],"next_cursor":"2021-02-02T02:45:53.000000Z,2888462"}